Objective
=========

Cartilage hypocellularity due to cell death contributes to the development of OA. Experimental exposure to MIA results in either chondrocyte necrosis (*in vitro*) or experimental OA with apoptosis when injected *ia* (*in vivo)*. As Hsp-70 is known to protect from cell death, we have evaluated the beneficial properties of its over-expression or induction in rat chondrocyte cells (RCC) after MIA exposure.

Methods
=======

*Cloning* rat Hsp-70 cDNA sequence into the plasmid pcDNA3.1/CT-GFP and transfection led to over expression of Hsp-70 with PEI agent. RT-PCR and Western blotting then monitored expression level of Hsp-70. *In vitro* and *in vivo* exposure of RCC to the proteasome inhibitor MG132 dramatically enhanced the induction of Hsp-70. *Protection* against MIA toxicity was analysed either after transfection of RCC with the vector or after pre-treatment of RCC with MG132. Cytotoxicity of MIA was evaluated by MTT and LDH tests. *In vivo assay*: on day 0, Wistar rats were injected *ia* with MG132, 2 hours before *ia* injection of MIA (0.3 and 0.03 mg). On Day 15, knees and patellae were carefully dissected for histological assessment.

Results
=======

*In vitro* MIA exposure led to cell death, rather by necrosis than by apoptosis (8%). Over-expression of Hsp-70 significantly protected from MIA toxicity in transfected cells after 24 and 48 hours respectively (28 and 64%). Moreover, preventive and curative MG132 (1.5 μM) pre-treatments preserved, at least in part, RCC from MIA chondrotoxicity in a dose-dependant manner related to the magnitude of Hsp-70 induction. *In vivo*, macroscopical evaluation of knees exposed to MIA demonstrated that MG132, when injected *ia* preventively, diminished the severity of OA-like chondral lesions on Day 15.

Conclusions
===========

*In vitro*, the over-expression (gene transfer) or the induction (MG 132) of Hsp-70 protects RCC from MIA cytotoxic-ity. Induction of Hsp-70 *in vivo* with MG 132 could be promising to modulate OA process and needs to be confirmed in rat experimental OA-models by using gene therapy (viral or non-viral).
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